ACIP still supports J&J coronavirus jab use

Friday, 23. July 2021 02:23

The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) expressed support for the continued use of the Johnson & Johnson coronavirus vaccine despite the low risk of causing a rare neurological condition.

According to the CDC, approximately 100 preliminary cases of Guillain-Barre syndrome were reported in J&J recipients in the United States. A total of 12.8 million shots of the vaccine were administered.

Additionally, the advisory panel said that it will recommend giving booster shots of the COVID-19 vaccine to immunocompromised people, but only after the Food and Drug Administration grants approval.

Related Links: Johnson & Johnson
Breaking the News / MD